Market Place
Sourcing Support
Calliditas Provides Setanaxib Patent Update
18 Jun 2024 //
PR NEWSWIRE
R&D Day: Setanaxib Anti-Fibrotic Effects, TARPEYO MoA
16 May 2024 //
PR NEWSWIRE
Calliditas announces positive topline results from phase 2 , setanaxib
07 May 2024 //
PHARMABIZ
Calliditas: Positive Phase 2 Head/Neck Cancer Data For NOX Inhibitor
06 May 2024 //
PR NEWSWIRE
Calliditas Receives Notice of Allowance for US Patent Covering Setanaxib
08 Apr 2024 //
PR NEWSWIRE
Calliditas’ setanaxib to receive US patent “Use of NOX Inhibitors for Cancer”
08 Apr 2024 //
PHARMABIZ
EMA Committee for Orphan Medicinal Products gives positive opinion on setanaxib
05 Oct 2023 //
PR NEWSWIRE
Calliditas granted orphan drug designation by the FDA for setanaxib
27 Sep 2023 //
PR NEWSWIRE
Calliditas announces supportive interim data from Phase 2 trial with setanaxib
13 Jul 2023 //
PR NEWSWIRE
First patient randomized in pivotal TRANSFORM study with setanaxib
15 Feb 2022 //
PRNEWSWIRE
Positive Phase 1 results in high-dose setanaxib trial
18 Jan 2021 //
PRNEWSWIRE
Genkyotex announces positive Phase 1 results demonstrating a favorable safety
18 Jan 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.